M&A

WeShop adds Booking.com and Expedia, letting you earn company stock on vacation bookings. But financial data reveals a turbulent journey ahead for shoppers.

With an oversubscribed offering, Bravo Mining is set to accelerate its Luanga project, capitalizing on strong investor confidence and a bullish metals market.

Sichenzia Ross Ference Carmel LLP leveraged its deep expertise in complex securities to advise on over $14 billion in deals, outperforming in a hot market.

A new PwC survey shows CEO optimism plummeting as most firms fail to monetize AI, while a select few reap huge rewards, widening a dangerous gap.

Toro Corp. paid a massive special dividend, exciting investors. We dig into the cash-vs-stock option, market reaction, and what it means for the firm's future.

An independent ruling ends a financial dispute over a 2022 divestment, freeing Agfa to inject fresh capital into its high-growth transformation strategy.

With gold and silver prices soaring, Summit Royalties makes a strategic move onto the US OTCQB market to fuel its ambitious acquisition-led growth plan.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

Bio-Rad's leadership will meet investors at the J.P. Morgan conference, facing questions on strategy and growth in a competitive, tech-driven market.

CDT Equity partners with a top advisory firm to license its drug-enhancing tech, tackling the patent cliff while managing a novel Bitcoin treasury strategy.

Hyatt finalizes a $2B asset sale to Tortuga Resorts, advancing its asset-light strategy while navigating hurricane recovery in the Caribbean.

The regional bank sold $360M in low-yield securities, accepting a major one-time loss to reinvest for higher returns and a stronger 2026 outlook.

With industry veteran Kevin Muskat at the helm, Leon Capital Group's new advisory practice promises M&A guidance free from audit firm conflicts.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

BrightView Holdings declared its eighth straight cash dividend, a move signaling financial discipline even as it navigates revenue challenges and stock volatility.

Oak Hill Advisors' record fundraise underscores a major shift in corporate finance, as private credit becomes the go-to capital source for large-cap firms.

A regulatory filing reveals a key investor's move in the Avadel bidding war, exposing the intense M&A hunger driving the future of health tech.

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?